| Title |
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2013
|
| DOI | 10.2147/ndt.s41596 |
| Pubmed ID | |
| Authors |
Michele Jara, Graham Barker, Herbert R Henney |
| Abstract |
Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experience is available from exposure of approximately 46,000 patients in the US from product approval through March 2011. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 3% |
| Unknown | 39 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 23% |
| Researcher | 5 | 13% |
| Student > Master | 4 | 10% |
| Other | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 7 | 18% |
| Unknown | 9 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 35% |
| Nursing and Health Professions | 5 | 13% |
| Psychology | 4 | 10% |
| Agricultural and Biological Sciences | 2 | 5% |
| Neuroscience | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 11 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,293
of 3,120 outputs
Outputs of similar age
#159,453
of 206,591 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#27
of 42 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.